Feb 21 |
Kazia concludes Phase 1 study for paxalisib early due to promising data
|
Feb 21 |
Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
|
Jan 18 |
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS
|
Dec 15 |
Kazia Therapeutics files to sell 591,697 ADSs for holders
|
Dec 5 |
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering
|
Dec 1 |
Kazia Therapeutics falls after announcing $2M direct offering
|
Dec 1 |
Kazia Therapeutics Announces $2 Million Registered Direct Offering
|
Nov 29 |
Kazia stock jumps after proposed license deal for paxalisib outside oncology
|
Nov 29 |
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
|
Nov 18 |
Kazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past week
|